Successful treatment of MDS-IB2 and chronic lymphocytic leukemia with venetoclax

Czech version

Authors: E. Šafránková ^1,2; P. Bělohlávková ^1,2; I. Fátorová ^1,2; P. Kašparová ^2,3
Published in: Transfuze Hematol. dnes,31, 2025, No. 2, p. 108-112.
Category: Case Reports
doi: https://doi.org/10.48095/cctahd2025prolekare.cz11

Overview

Venetoclax is a BCL2 inhibitor approved for the treatment of chronic lymphocytic leukaemia / small lyphocytic lymphoma (CLL/SLL) and acute myeloid leukaemia (AML). However, its therapeutic potential is revealed by preliminary results of clinical trials even in the diagnosis of high-risk myelodysplastic syndrome (MDS). The case report provides information about a patient where the therapeutic approach for the primary diagnosis of CLL supported the use of venetoclax in the treatment of high-risk MDS. This approach allowed the patient to achieve remission of both diseases and perform an allogeneic transplantation of hematopoietic cells.

Keywords:

venetoclax – myelodysplastic syndrome – chronic lymphocytic leukaemia – azacitidine – allogeneic haematopoietic cell transplantation

Sources

1. Hasserjian RP, Germing U, Malcovati L. Diagnosis and classification of myelodysplastic syndromes. Blood. 2023; 142 (26): 2247–2257. doi: 10.1182/blood.2023020078.

2. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022; 36: 1703–1719. doi: 10.1038/s41 375-022-01613-1.

3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes. NCCN. Verze 1.2024.

4. Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic system for myelodysplastic syndromes. New Engl J Med Evid. 2022; 1 (7): 1–14. doi: 10.1056/EVIDoa2200008.

5. Bělohlávková P. Možnosti léčby myelodysplastického syndromu v roce 2021. Vnitř Lék. 2021; 67 (3): 150–155. doi: 10.36290/vnl.2021.036.

6. Nachtkamp K, Kobbe G, Gattermann N, Germing U. Myelodysplastic syndromes new methods of diagnosis, prognostication, and treatment. Dtsch Arztebl Int. 2023; 120 (12): 203–210. doi: 10.3238/arztebl.m2023.0005.

7. FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia. U.S. Food and Drug Administration. 2020. https: //www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia.

8. Zeidan, AM, Borate U, Pollyea DA, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023; 98 (2): 272–281. doi: 10.1002/ajh.26771.

9. Du Y, Li C, Yan J. The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. Hematology. 2023; 28 (1): 2198098. doi: 10.1080/16078454.2023.2198098.

10. Study of venetoclax tablet with intravenous or subcutaneous azacitidine to assess change in disease activity in adult participants with newly diagnosed higher-risk myelodysplastic syndrome (Verona). ClinicalTrials.gov. 2024; https: //ichgcp.net/clinical- trials-registry/NCT04401748.

11. Cazaceanu O, Iova A, Vladareanu AM, Onisai M, Enache C, Andrus E. Chronic lymphocytic leukemia followed by myelodysplastic syndrome and erythroleukemia. J Med Life. 2012; 5: 6–11.

12. Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020; 21 (9): 1188−1200. doi: 10.1016/S1470-204 5 (20) 30443-5.

PODÍL AUTORŮ NA PŘÍPRAVĚ RUKOPISU

EŠ – autor textu

PB – spoluautor

IF, PK – autoři obrázkové dokumentace

Do redakce doručeno dne: 29. 12. 2024.

Přijato po recenzi dne: 31. 3. 2025.

MUDr. Eliška Šafránková

Za Betlémem 439

524 01 Žacléř

e-mail: eliska.safrankova@fnhk.cz